id,filing_uuid,filing_type,registrant_name,registrant_id,client_name,filing_year,filing_period,issue_code,specific_issues,government_entities,income_amount,expense_amount,is_no_activity,is_termination,received_date
3801209,50825527-9266-4fca-acaf-cb2906eeb942,Q1,AMERICAN ACADEMY OF AUDIOLOGY,79370,AMERICAN ACADEMY OF AUDIOLOGY,2026,first_quarter,MED,Prevention of elimination of NIH funding FY'2026 LHHS Appropriations Act Early Hearing Detection Intervention Program,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2026-03-17T15:17:05-04:00
3801244,58bf05f8-c0ad-4b0f-b7b9-78267e1406ac,1A,AMERICAN ACADEMY OF AUDIOLOGY,79370,AMERICAN ACADEMY OF AUDIOLOGY,2026,first_quarter,MED,"Prevention of elimination of NIH funding FY'2026 LHHS Appropriations Act Early Hearing Detection Intervention Program HR 6718, Professional Student Loan Legislation","Education, Dept of,HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2026-03-24T10:50:16-04:00
3801405,9269e7d3-5465-4208-878f-824c43348f4b,Q1,NELSON MULLINS RILEY & SCARBOROUGH,285871,"ANBEX, INC.",2026,first_quarter,MED,Stockpile potassium iodide to counteract effects of nuclear radiation.,"HOUSE OF REPRESENTATIVES,SENATE",15000,,0,0,2026-03-31T10:20:31-04:00
3801420,32838a64-46ca-4776-9bbc-b95aa4889be2,Q1,MCDERMOTT+ LLC,401103287,VERILY LIFE SCIENCES LLC,2026,first_quarter,MED,"Efforts relating to artificial intelligence, wastewater surveillance, and drug device innovation.","Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2026-03-31T11:18:11-04:00
3801497,3e04fbbc-9474-4f35-9400-0f9af96ff694,Q1,"REPUBLIC CONSULTING, LLC",401016871,IQVIA,2026,first_quarter,MED,Monitor health data budgets and policy.,"Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2026-03-31T17:58:40-04:00
3801736,5ee903be-9d32-4ae7-b26a-8082e7039291,Q1,"AUBURN HEALTH STRATEGIES, LLC",292697,AMERICAN PROFICIENCY INSTITUTE,2026,first_quarter,MED,proficiency testing for clinical laboratories,"Centers For Medicare and Medicaid Services (CMS),Office of Management & Budget (OMB)",,,0,0,2026-04-01T15:11:16-04:00
3801766,588746ab-f44e-44bd-abc2-a8796efa28f2,Q1,"MAGILL ASSOCIATES, LLC",401103511,THE LIVINGSTON GROUP ON BEHALF OF INNOVATIVE VACCINE TECHNOLOGIES,2026,first_quarter,MED,FY 2027 appropriations for the development of a synthetic vaccine,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2026-04-01T16:24:01-04:00
3801784,9a835b5e-2b2a-4691-9f5c-cf9a3325ecc4,Q1,ESHAM STRATEGIES LLC,401109169,"ACCUMULUS SYNERGY, INC.",2026,first_quarter,MED,Issues related to regulatory information exchange policies.,,20000,,0,0,2026-04-01T18:54:55-04:00
3801807,db9eadc1-42de-444d-85eb-7d9478453c88,Q1,CURE SMA,401104586,CURE SMA,2026,first_quarter,MED,"medical research in spinal muscular atrophy, development and approval of spinal muscular atrophy treatments, National Institutes of Health funding, U.S. Department of Defense peer reviewed research in spinal muscular atrophy, U.S. Department of Defense Congressionally Directed Medical Research Program funding, Medical Research for Our Troops Act (H.R. 3906)","Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",,75000,0,0,2026-04-01T21:02:59-04:00
3802253,bb906345-b5f5-4843-ae26-5456d09de7e4,Q1,DQB INTERNATIONAL,291834,TEXAS BIOMEDICAL RESEARCH INSTITUTE,2026,first_quarter,MED,"FY 2027 Labor, HHS Appropriations Bill","HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2026-04-03T12:38:31-04:00
3802335,9c7fbae9-442a-40be-bdb6-83e8bc7e24e1,Q1,RAY C CULVER III,11468,ARKANSAS CHILDREN'S HOSPITAL,2026,first_quarter,MED,"USDA ARS Human Nutrition Research funding in the FY2026 Agriculture Appropriations (P.L. 119-37) and in the developing FY2027 Agricultural Appropriations bill. USDA ARS Human Nutrition Research funding authority in the reauthorization of the Agriculture Improvement Act of 2018, P.L. 115-334.","HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2026-04-03T23:19:55-04:00
3802620,58510a27-6378-4fdf-a0e3-f68305b77605,Q1,AMERICAN COLLEGE OF CLINICAL PHARMACY,57258,AMERICAN COLLEGE OF CLINICAL PHARMACY,2026,first_quarter,MED,Focus interactions with the Agency for Healthcare Research and Quality (AHRQ) on the issue of Quality of Medication Therapy Management Services delivered programs authorized by the Patient Protection and Affordable Care Act (PPACA PL 111-148) and Medicare Part D plans.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,144981,0,0,2026-04-06T11:07:36-04:00
3802762,2a97fede-b396-4761-a1e4-804347603a63,Q1,SQUIRE PATTON BOGGS,30906,ALLIANCE FOR BIOSECURITY,2026,first_quarter,MED,Preparedness and response as it relates to Biosecurity.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",70000,,0,0,2026-04-06T14:19:01-04:00
3802956,a5b8c0db-2e9e-4fb5-aae5-c7458d84c34c,Q1,BLUEBIRD STRATEGIES,401105447,MYOTONIC,2026,first_quarter,MED,Funding for myotonic dystrophy research as part of the FY27 Congressionally Directed Medical Research Program & Peer Review Medical Research Program.,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2026-04-06T16:44:57-04:00
3802970,d324f04a-945b-4611-9776-cfe4de36c560,Q1,BLUEBIRD STRATEGIES,401105447,NCATS ALLIANCE,2026,first_quarter,MED,FY27 NIH/NCATS Appropriations Funding,"HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",,,0,0,2026-04-06T16:49:30-04:00
3803112,6a556780-41ae-47c9-ade6-b7747fe2e8f8,Q1,SQUIRE PATTON BOGGS,30906,"LA MAESTRA FOUNDATION ON BEHALF OF LA MAESTRA FAMILY CLINIC, INC.",2026,first_quarter,MED,Funding support for federally qualified health centers; reauthorization of programs,,20000,,0,0,2026-04-07T08:24:30-04:00
3803236,28ff982d-f5ce-42b2-88ae-def42f7b799e,Q1,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,HAZELDEN BETTY FORD FOUNDATION,2026,first_quarter,MED,Educate key government stakeholders on Hazelden Betty Ford Foundation activities in support of substance use and mental health for US Servicemembers and Veterans.,"Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2026-04-07T12:45:10-04:00
3803376,dcb6eba5-9571-4cab-b784-1c876d6cf25b,Q1,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,THE UNIVERSITY OF TEXAS SYSTEM,2026,first_quarter,MED,"Assessing the Systems R&D funding opportunities, designing strategies to pursue funding, and securing funding for research priorities.","HOUSE OF REPRESENTATIVES,SENATE",90000,,0,0,2026-04-07T15:25:19-04:00
3803662,f5122c13-ed21-40fc-b59a-367df1ae7c01,Q1,GRANITE CAPITOL CONSULTING LLC,401108946,QURALIS,2026,first_quarter,MED,FDA Related Issues,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2026-04-08T08:41:33-04:00
3803721,a45c0915-6ca3-408e-a5b1-482af2d87dd3,Q1,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,MMV MEDICINES FOR MALARIA VENTURE,2026,first_quarter,MED,The purpose was to increase funding for malaria research in the Department of Defense.,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2026-04-08T09:53:29-04:00
3803783,ba067a96-5a5e-4fa4-bf2f-15b81b50ee55,Q1,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,"RADIATRIC, INC.",2026,first_quarter,MED,Issues related to funding for photonics research.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2026-04-08T11:13:45-04:00
3803794,41828542-8cd8-45dd-83bd-f9451370c382,Q1,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,THE UNIVERSITY OF TEXAS AT SAN ANTONIO,2026,first_quarter,MED,Identify federal funding opportunities and partnerships with federal agencies.,"Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2026-04-08T11:16:12-04:00
3803995,9774c6a7-9901-496c-b7eb-3c9e7e3500b2,Q1,AMERICAN GASTROENTEROLOGICAL ASSOCIATION,59650,AMERICAN GASTROENTEROLOGICAL ASSOCIATION,2026,first_quarter,MED,"Lobbied in support in increased funding for biomedical research in the VA, NIH and DoD","HOUSE OF REPRESENTATIVES,SENATE",,80000,0,0,2026-04-08T13:43:01-04:00
3804449,827572e9-bbdb-45be-8f01-cacd8c9447ee,Q1,"PARK GOVERNMENT RELATIONS, LLC",401106398,"MEDICOM TECHNOLOGIES, INC",2026,first_quarter,MED,clinical image exchange,HOUSE OF REPRESENTATIVES,60000,,0,0,2026-04-09T08:40:30-04:00
3804598,d71cea87-37a2-459e-8014-7cc440652c32,Q1,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,CASE WESTERN RESERVE UNIVERSITY,2026,first_quarter,MED,"Issues related to the FAIR model, federal grants and general higher education issues.","HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2026-04-09T12:19:09-04:00
3805064,ecad0ae0-6d38-49cf-b9c4-0a0aca56322c,Q1,CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER,312496,CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER,2026,first_quarter,MED,"vaccines, ACIP, 340B, cdc reform, nih reform, pediatric research, NIH budget, FAIR Act, indirect costs, whole genome sequencing, high cost drugs, CMMI","Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,White House Office",,28548,0,0,2026-04-10T09:08:04-04:00
3805336,55ab303c-980b-4d65-9a4e-b8e5c3c205a2,Q1,GLAUKOS CORPORATION,401108368,GLAUKOS CORPORATION,2026,first_quarter,MED,Legislation regarding FDA regulation of combination products H.R. 1261/ S. 3302 Mikaela Naylon Give Kids a Chance Act Bill,"HOUSE OF REPRESENTATIVES,SENATE",,280000,0,0,2026-04-10T12:06:26-04:00
3805476,82421802-af14-400d-800b-013c6e175009,Q1,UNIVERSITY OF KENTUCKY,400287372,UNIVERSITY OF KENTUCKY,2026,first_quarter,MED,NIH Funding FY26,"HOUSE OF REPRESENTATIVES,SENATE",,70000,0,0,2026-04-10T14:24:32-04:00
3806039,886848fc-f82c-484d-b522-e456d9f00425,Q1,FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC),86196,"INTUITIVE SURGICAL, INC.",2026,first_quarter,MED,Lobbying related to health care issues.,,40000,,0,0,2026-04-13T09:28:45-04:00
3806096,8e027f09-c18f-4a24-baad-72ed3812432c,Q1,"FEDERAL SOLUTIONS, LLC",311371,MISSISSIPPI STATE UNIVERSITY,2026,first_quarter,MED,Labor/HHS/Education Appropriations: Provisions relating to disease research,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2026-04-13T10:05:16-04:00
3806439,7b3ac8bd-689f-4b43-b058-dcf2e1ed8003,Q1,IPOLICY SOLUTIONS,401105127,ASSOCIATION FOR MOLECULAR PATHOLOGY,2026,first_quarter,MED,No bill #: legislation to clarify CLIA,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",70500,,0,0,2026-04-13T13:49:05-04:00
3806469,92fbb00f-0ece-4e1b-9b61-316cb11d2bc3,Q1,IPOLICY SOLUTIONS,401105127,GUARDANT HEALTH INC.,2026,first_quarter,MED,FDA-2025-N-4622 Immunology and Microbiology Devices; Reclassification of Nucleic Acid-Based Test Systems for Use with a Corresponding Approved Oncology Therapeutic Product; Proposed Amendment; Proposed Order,Food & Drug Administration (FDA),16000,,0,0,2026-04-13T13:58:10-04:00
3806832,74e6e128-165e-4f5c-8f66-29bf59941753,Q1,AMERICAN SOCIETY FOR CLINICAL PATHOLOGY,3435,AMERICAN SOCIETY FOR CLINICAL PATHOLOGY,2026,first_quarter,MED,Medicare; Electronic Health Records/Health Information Technology; Medicare Access and CHIP Reauthorization; Protecting Access to Medicare Act; Medicare Physician and Clinical Laboratory Fee Schedules; Medicare Quality Payment Program; Medicare National and Local Coverage Determinations; Federal Oversight of Laboratory Tests including Laboratory Developed Testing Services; Physician and Clinical Laboratory Personnel Shortages/workforce issues; Education and Loan Repayment Programs; Appropriations for Federal Agencies; Global Health Initiative; Laboratory Access for Beneficiaries Act; Clinical Laboratory Improvement Amendments; Laboratory oversight; COVID-19 Response and Laboratory Testing Capacity; Communicable Diseases and Pandemic Preparedness; Stark Self-Referral Reform; the RESULTS Act,"Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA)",,46000,0,0,2026-04-13T17:26:20-04:00
3806854,734a1e67-53b4-4594-a2d6-73923a374958,Q1,PARALYZED VETERANS OF AMERICA,30724,PARALYZED VETERANS OF AMERICA,2026,first_quarter,MED,"Discussions: Department of Veterans Affairs, Medical Research Issues Discussions: National Institutes of Health, Medical Research Issues","HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,Veterans Affairs, Dept of (VA)",,108181,0,0,2026-04-13T18:01:45-04:00
3807081,841fd8f3-3034-44b9-a80e-0a86b95396d5,Q1,"EFB ADVOCACY, LLC",401104430,ASSOCIATION OF AMERICAN CANCER INSTITUTES,2026,first_quarter,MED,Issues related to biomedical research National Institutes of Health appropriations funding,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",22500,,0,0,2026-04-14T09:20:30-04:00
3807099,98810b56-db35-41c2-b7c7-a067d3a8ca13,Q1,"EFB ADVOCACY, LLC",401104430,UNITED FOR MEDICAL RESEARCH,2026,first_quarter,MED,Funding Issues related to the National Institutes of Health,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2026-04-14T09:25:57-04:00
3807531,c72f75e7-93db-4836-9f6f-820489adc36b,Q1,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,AMERICAN SOCIETY FOR RADIATION ONCOLOGY,2026,first_quarter,MED,Discussions regarding patient access to radiation oncology.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES",50000,,0,0,2026-04-14T13:00:57-04:00
3807668,2101f946-98fb-4776-8ca3-fe38922225f0,Q1,MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP),24486,"OSTEAL THERAPEUTICS, INC.",2026,first_quarter,MED,General federal government relations,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2026-04-14T13:46:17-04:00
3808292,5f7a1bc9-e949-4be4-b32e-73c9a2798741,Q1,IMPACT MANAGEMENT GROUP,401104137,"CENTRAL ARKANSAS RADIATION THERAPY INSTITUTE, INC.",2026,first_quarter,MED,On behalf of Client support continued and future funding for CARTI in Arkansas,HOUSE OF REPRESENTATIVES,,,0,0,2026-04-14T17:31:14-04:00
3808309,52ce476a-9ccb-40ed-812a-a11d6dc0e6a6,Q1,IMPACT MANAGEMENT GROUP,401104137,ARKANSAS RESEARCH ALLIANCE,2026,first_quarter,MED,On behalf of client support continued and future funding for clinical research programs in Arkansas,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2026-04-14T17:38:40-04:00
3808352,d4dcb2ec-8b4d-4ae1-8cf3-2009ed81ff4d,Q1,"TERRAPOWER, LLC",401109474,"TERRAPOWER, LLC",2026,first_quarter,MED,"Implementation of H.R. 3684, Infrastructure Investment and Jobs Act (IIJA); Implementation of H.R 5376 - Inflation Reduction Act of 2022; Implementation of S. 870 - Fire Grants and Safety Act of 2023; Implementation of H.R.1042 - Prohibiting Russian Uranium Imports Act; Implementation of H.R. 1 - One Big Beautiful Act; FY26 Appropriation; Implementation of H.R. 6938 - Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026 FY27 Appropriations","Commerce, Dept of (DOC),Energy, Dept of,HOUSE OF REPRESENTATIVES,SENATE",,200000,0,0,2026-04-14T17:47:39-04:00
3808388,ac487c4d-90db-4226-ade3-1ac0a49b1a52,Q1,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,"LILA SCIENCES, INC.",2026,first_quarter,MED,"Identifying federal funding and legislative opportunities to support scientific superintelligence coupled with autonomous laboratory environments working in life, chemical, and material sciences.","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2026-04-14T17:57:58-04:00
3808487,7050e842-fed3-404e-9616-3f20f4854900,Q1,BALLARD PARTNERS,401104288,BIOSTAR MEDICAL LLC,2026,first_quarter,MED,Promoting the advancement of healthcare technology.,"Health & Human Services, Dept of (HHS)",300000,,0,0,2026-04-14T19:41:27-04:00
3808591,c635e12d-b619-4f86-98a3-d08a584cfa4d,Q1,"WISE CAPITAL STRATEGY, LLC",401105210,AMITY HOLDINGS LLC DBA PIP DIABETES CARE,2026,first_quarter,MED,Healthcare and trade issues which may impact efforts to make diabetes care products more accessible.,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2026-04-14T22:36:09-04:00
3808658,b5326e89-bbc1-41d2-8020-6a9817c92b9d,Q1,AMERICAN SOCIETY OF ADDICTION MEDICINE,401104864,AMERICAN SOCIETY OF ADDICTION MEDICINE,2026,first_quarter,MED,"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.","Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)",,40000,0,0,2026-04-15T08:09:07-04:00
3809059,76bd107c-d9f3-4d65-a60c-8876ffe501a3,Q1,"F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES",18411,F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES,2026,first_quarter,MED,"(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough","HOUSE OF REPRESENTATIVES,SENATE",,160000,0,0,2026-04-15T11:32:42-04:00
3809069,e9af38b7-6745-4ab0-b9a8-c1e6a31c87f0,Q1,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,THE UNITED STATES PHARMACOPEIAL CONVENTION,2026,first_quarter,MED,Issues related to strengthening the resiliency of the U.S. medical supply chain.,"Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2026-04-15T11:39:43-04:00
3809124,662af182-57c1-4857-b559-02f670205e83,Q1,"RICHARD J. SCHOLZ, P.A. (FKA JACOBS SCHOLZ & WYLER, LLC)",400361684,PPLA,2026,first_quarter,MED,Medical/Disease Research/Clinical Labs,Food & Drug Administration (FDA),31250,,0,0,2026-04-15T11:53:07-04:00
3809227,b5673f29-d451-48ca-9bbd-3ca5529138d8,Q1,LIVE OAK STRATEGIES,401105683,KIMERA LABS,2026,first_quarter,MED,Issues related to lab safety.,"HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2026-04-15T12:16:30-04:00
3809318,99a5fb19-f938-477d-9f7d-a4f0b5b5e0c3,Q1,ASSOCIATION FOR DIAGNOSTICS & LABORATORY MEDICINE (FORMERLY AACC),1466,ASSOCIATION FOR DIAGNOSTICS & LABORATORY MEDICINE (FORMERLY AACC),2026,first_quarter,MED,"* In January 2026, ADLM conducted a grassroots campaign urging it members write to Congress in support of H.R.5269/S.2761, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, which would create a new, more equitable Medicare clinical laboratory fee schedule.","HOUSE OF REPRESENTATIVES,SENATE",,120000,0,0,2026-04-15T12:56:04-04:00
3809443,3f5116a0-5b24-44c3-bbea-c24be3836ad0,Q1,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,"ADVANCED MATERIALS AND DEVICES, INC.",2026,first_quarter,MED,Educated key government stakeholders on AMADs products applicable to the military and supported Defense appropriations requests.,"Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2026-04-15T13:37:40-04:00
3809449,8ce3d769-fad2-441d-a50d-0246f6f60c86,Q1,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,DEFENSE HEALTH RESEARCH CONSORTIUM,2026,first_quarter,MED,"HR 7148, FY26 Consolidated Appropriations Act, HR/S unnumbered, FY27 Defense Appropriations Act, Defense Health Research Programs","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2026-04-15T13:39:18-04:00
3809480,80c0ce5a-c8e4-46e2-8b8e-515d3f5b4f8f,Q1,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,MEDICAL TECHNOLOGY ENTERPRISE CONSORTIUM,2026,first_quarter,MED,Educated key government stakeholders on the Medical Technology Enterprise Consortiums activities and partnership model in support of Servicemember health and readiness; support Defense appropriations.,"Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2026-04-15T13:48:50-04:00
3809504,1d745de7-d255-403f-860b-309032eebd13,Q1,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,"MEDIVIEW XR, INC.",2026,first_quarter,MED,Educated government stakeholders on Mediviews technology and capabilities in support of clinical training and graduate medical education; support Defense appropriations.,"Defense, Dept of (DOD)",40000,,0,0,2026-04-15T13:52:23-04:00
3809520,4094b28b-8545-444e-8fcf-cc693b329828,Q1,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,"NIRSENSE, LLC (FKA BIONICA LABS)",2026,first_quarter,MED,Educated key government stakeholders on NIRSenses activities and technologies in support of the Armed Forces and support Defense appropriations requests.,"Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2026-04-15T13:53:55-04:00
3809533,b5d6013b-3852-4b80-8e9d-925827bb16a7,Q1,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,"OCTAPHARMA USA, INC.",2026,first_quarter,MED,Educated government stakeholders on Octapharmas product and manufacturing capabilities in support of National Security.,"Defense, Dept of (DOD),Executive Office of the President (EOP),SENATE",90000,,0,0,2026-04-15T13:57:36-04:00
3809559,0e50f8fd-66af-4c90-8b0b-bddbb55b77af,Q1,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,SMITH & NEPHEW,2026,first_quarter,MED,Educated key government stakeholders on Smith+Nephew products applicable to the military and support appropriations and authorization requests.,"Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2026-04-15T14:03:59-04:00
3809568,42140d67-f257-4ad0-9986-9f5f5b6f14e3,Q1,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,PANCREATIC CANCER ACTION NETWORK (PANCAN),2026,first_quarter,MED,"H.R. 7148, FY 2026 Consolidated Appropriations Act, Pancreatic Cancer Research Program and NIH research on pancreatic cancer;H.R./S. Unnumbered, FY 2027 Defense Appropriations Act, Pancreatic Cancer Research Program; H.R./S. Unnumbered FY 2027 Labor-Health and Human Services-Education Appropriations Act, NIH research on pancreatic cancer","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2026-04-15T14:04:50-04:00
3809572,721721c7-af59-4ac6-9f5a-e75d27a70f83,Q1,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,TELEFLEX INCORPORATED,2026,first_quarter,MED,Educated key government stakeholders on Teleflexs research and development capabilities in support of US Service members.,"Defense, Dept of (DOD)",20000,,0,0,2026-04-15T14:05:39-04:00
3809577,baa3c1b2-2cbd-4d50-bcec-42a2ebbb49be,Q1,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,FOUNDATION FOR PERIPHERAL NEUROPATHY,2026,first_quarter,MED,"H.R. 7148, FY 2026 Consolidated Appropriations Act, Peer Reviewed Medical Research Program designation for peripheral neuropathy and NIH research on peripheral neuropathy; H.R./S. Unnumbered, FY 2027 Defense Appropriations Act, Peer Reviewed Medical Research Program designation for peripheral neuropathy;H.R./S. Unnumbered, FY 2027 Labor-Health and Human Services-Education Appropriations Act, NIH research on peripheral neuropathy","HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",30000,,0,0,2026-04-15T14:07:39-04:00
3809580,004dcebf-806d-4831-9cf3-7a35099f9d82,Q1,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,THE GENEVA FOUNDATION,2026,first_quarter,MED,Educated key government stakeholders on The Geneva Foundations research and development activities in support of US Service members; support Defense appropriations.,"Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2026-04-15T14:07:48-04:00
3809586,cec09168-686d-4bb6-94b2-4b074270a7c2,Q1,TEAM HALLAHAN LLC,401104228,THE ROOSEVELT GROUP (ON BEHALF OF LSU HEALTH SCIENCES FOUNDATION),2026,first_quarter,MED,"Research and development efforts and FY 26 and FY 27 Appropriations inside the DOD, HHS/NIH, VA. PACT Act Implementation; community project funding for high performance computing center.","Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",,,0,0,2026-04-15T14:09:16-04:00
3809591,b91ca917-12cf-4ccc-bd08-6b8ebc5c57e0,Q1,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,THE REGENTS OF THE UNIVERSITY OF COLORADO OBO UNIVERSITY OF COLORADO ANSCHUTZ,2026,first_quarter,MED,Educated key government stakeholders on the University's medical capabilities in areas applicable to military health and readiness. Supported Defense authorizations and appropriations.,"Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2026-04-15T14:10:14-04:00
3809602,1f6348b2-2741-4c7d-be8c-271a5b12c507,Q1,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,TUBEROUS SCLEROSIS ALLIANCE,2026,first_quarter,MED,"H.R. 7148, FY 2026 Consolidated Appropriations Act,Tuberous Sclerosis Complex Research Program and NIH and CDC funding for tuberous sclerosis complex research and surveillance ;H.R./S. Unnumbered, FY 2027 Defense Appropriations Act, Tuberous Sclerosis Complex Research Program; H.R./S. Unnumbered, FY 2027 Labor-Health and Human Services-Education Appropriations Act, NIH and CDC funding for tuberous sclerosis complex research and surveillance","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2026-04-15T14:15:07-04:00
3809617,e3a4b541-76b6-46f9-b4a3-b9fa77cb04f8,Q1,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,WASHINGTON STATE UNIVERSITY,2026,first_quarter,MED,Educated key government stakeholders on WSUs research and development activities in support of US Service members; support Defense appropriations.,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2026-04-15T14:16:55-04:00
3809618,90c40060-c392-4c37-8ab8-7180d9d19083,Q1,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,VHL ALLIANCE,2026,first_quarter,MED,"H.R. 7148, FY 2026 Consolidated Appropriations Act, Peer Reviewed Medical Research Program designation for VHL and NIH research on Von Hippel-Lindau syndrome;H.R./S. Unnumbered, FY 2027 Defense Appropriations Act, Peer Reviewed Medical Research Program designation for VHL; H.R./S. Unnumbered, FY 2027 Labor-Health and Human Services-Education Appropriations Act, NIH research on Von Hippel-Lindau syndrome","HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2026-04-15T14:17:32-04:00
3809647,cb4bc14c-5589-4e21-b745-d8fd15b80762,Q1,ADAPTIVE GOVERNMENT RELATIONS,401110179,SEATTLE CHILDREN'S,2026,first_quarter,MED,NIH and pediatric research,"HOUSE OF REPRESENTATIVES,SENATE",54000,,0,0,2026-04-15T14:21:47-04:00
3809681,48e07218-4e21-4b1f-b655-0a8947eeb450,Q1,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,"GINKGO BIOWORKS, INC.",2026,first_quarter,MED,"Educated key government stakeholders on Ginkgo Bioworks capabilities in support of wastewater surveillance, and biomanufacturing; support authorization language and appropriations for Defense and Labor, Health, Human Services and Education.","Defense, Dept of (DOD),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2026-04-15T14:31:54-04:00
3809737,f5c0bdb4-1db5-42f1-a337-1b2547b0e759,Q1,"THE CORMAC GROUP, LLC",66773,KESSLER FOUNDATION,2026,first_quarter,MED,"appropriations, DOD, TBI research, veterans issues","Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2026-04-15T14:48:14-04:00
3809740,db301dbb-818d-4234-853b-0a96dc89fedc,Q1,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,CHILDREN'S NATIONAL MEDICAL CENTER,2026,first_quarter,MED,"Health-related issues including reimbursement, research, public-health & clinical care.","Education, Dept of,Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office",50000,,0,0,2026-04-15T14:48:47-04:00
3809760,e8ee3331-471f-429e-9dab-0ff9cce9c81d,Q1,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,CITY OF HOPE MEDICAL CENTER,2026,first_quarter,MED,Issues related to Medicare/Medicaid reimbursement and clinical research.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2026-04-15T14:50:10-04:00
3810117,d0cbdd33-14e7-455c-8ec7-39497a36ba8a,Q1,CHECKMATE GOVERNMENT RELATIONS,401109039,SANOFI US SERVICES INC.,2026,first_quarter,MED,There is no current bill filed. Working on Issues related to health care and drug pricing.,"Centers For Medicare and Medicaid Services (CMS),Commerce, Dept of (DOC),Health & Human Services, Dept of (HHS),U.S. Trade Representative (USTR),White House Office",90000,,0,0,2026-04-15T15:58:05-04:00
3810266,948fec89-9493-4568-b44a-44bc490a296a,1T,CHECKMATE GOVERNMENT RELATIONS,401109039,VANTIVE HEALTH LLC,2026,first_quarter,MED,There is no current bill filed. Focused engagement with HHS for medical technologies regarding organ support devices.,"Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),White House Office",110000,,0,1,2026-04-15T16:12:38-04:00
3810336,35febaeb-7d19-462b-8697-66718f183a5d,Q1,"THE AMERICAN OCCUPATIONAL THERAPY ASSOCIATION, INC. (AOTA)",2970,"THE AMERICAN OCCUPATIONAL THERAPY ASSOCIATION, INC. (AOTA)",2026,first_quarter,MED,No bill number - Urge NIH to continue funding for therapy research,Natl Institutes of Health (NIH),,189000,0,0,2026-04-15T16:18:36-04:00
3810982,243d6b1e-43e4-4ea4-9c42-9afb0a1319ca,Q1,BALLARD PARTNERS,401104288,"INSIGHTEC, INC.",2026,first_quarter,MED,Guidance on legislation and regulations regarding medical devices; advocacy regarding the use of medical devices at the VA.,"HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA)",90000,,0,0,2026-04-15T21:21:17-04:00
3811037,c7c44c6d-f572-48ca-bf5a-d31dddd4cf59,Q1,ACORN CONSULTING,401107972,"THORAGENIX INNOVATIONS, INC.",2026,first_quarter,MED,Advancing study and approval for medical devices,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2026-04-15T22:14:54-04:00